Inflammatory response and C‑ reactive protein value in patient with acute coronary syndrome

Česká verzia

Authors: L. Kubková ^1,2; J. Špinar ^1,2; M. Pávková Goldbergová ³; J. Jarkovský ⁴ ; J. Pařenica ^1,2
Authors place of work: Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Jindřich Špinar, CSc., FESC ¹; Mezinárodní centrum klinického výzkumu, FN u sv. Anny Brno, ředitel MUDr. Goraz Stokin ²; Ústav patologické fyziologie LF MU Brno, přednostka prof. MU Dr. Anna Vašků, CSc. ³; Institut biostatistiky a analýz LF MU Brno, ředitel doc. RNDr. Ladislav Dušek, Ph. D. ⁴
Published in the journal: Vnitř Lék 2013; 59(11): 981-988
Category: Review

Summary

Inflammation plays an important role in the pathophysiology of acute coronary syndrome as well as in the process of atherosclerosis in general. At the moment of myocardial ischaemia, local and systemic inflammatory reaction is amplified; in ischaemic myocardium there is increased expression of proinflammatory cytokines, particularly interleukin-6, which mediates C‑ reactive protein (CRP) production by hepatocytes. CRP activates the complement cascade and thereby contributes to the lysis and removal of damaged cardiomyocytes. Whereas in a healthy population CRP levels range from 1.2 to 2.0 mg / l, in patients with ACS the levels of CRP significantly increase with the peak of 2nd to 4th day from the onset of myocardial infarction. Peak CRP levels ranged from 20 to 250 mg / l in patients with STEMI treated conservatively, the median of peak of CRP levels was 79 mg/ l in patients with anterior wall STEMI treated with primary PCI. There is a recommendation of CRP evaluation within the early risk stratification of patients with ACS according to the current ESC guidelines. In patients with NSTEMI, CRP levels > 10 mg/ l are associated with increased long‑term mortality. In patients with STEMI treated with primary PCI, CRP levels > 79 mg/ l could predict negative left ventricle remodelation. The predictive value of GRACE risk score was improved using CRP, levels > 22 mg/ l predicted worse prognosis in patients with either STEMI or NSTEMI treated invasively. However, if also cardiac troponin and natriuretic peptides in addition to GRACE risk score were used, CRP levels were useless in further risk stratification improvement. In clinical practice, in terms of coinciding infection, problems with CRP levels interpretetation can occur as well. Several patients either in cardiogenic shock or after cardiopulmonary resuscitation have signs of systemic inflammatory response, and sometimes it is very difficult to decide whether there is a necessity to iniciate the antibiotic therapy because of infectious cause. In patients after cardiopulmonary resuscitation, CRP levels > 180 mg/ l indicate highly probable infection, but with the poor sensitivity. For patients in cardiogenic shock, procalcitonin appears to be more useful for the detection of infection; in this group of patients, procalcitonin levels > 2 ng/ ml are common, and levels > 10 ng/ ml indicate infection undoubtedly.

Key words:
C‑ reactive protein – myocardial infarction – prognosis – infectious complications

Zdroje

1. Widimsky P, Zelizko M, Jansky P et al. The incidence, treatment strategies and outcomes of acute coronary syndromes in the “reperfusion network” of different hospital types in the Czech Republic: results of the Czech evaluation of acute coronary syndromes in hospitalized patients (CZECH) registry. Int J Cardiol 2007; 119: 212– 219.

2. Pařenica J, Kala P, Jarkovský J et al. Akutní srdeční selhání a časný rozvoj dysfunkce levé komory u pacientů s akutním infarktem myokardu s elevacemi ST léčených primární perkutánní koronární intervencí. Vnitř Lék 2011; 57: 43– 51.

3. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‑segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST‑segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999– 3054.

4. Morrow DA, Cannon CP, Jesse RL et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007; 115: e356– e375.

5. Hochman JS, Sleeper LA, Webb JG et al. Early revascularization and long‑term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295: 2511– 2515.

6. Kohsaka S, Menon V, Lowe AM et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005; 165: 1643– 1650.

7. Reynolds HR, Hochman JS. Cardiogenic Shock: current concepts and improving outcomes. Circulation 2008; 117: 686– 697.

8. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115– 126.

9. Wennberg P, Wensley F, Di Angelantonio E et al. Haemostatic and inflammatory markers are independently associated with myocardial infarction in men and women. Thromb Res 2012; 129: 68– 73.

10. Ono K, Matsumori A, Shioi T et al. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998; 98: 149– 156.

11. Bürger A, Benicke M, Deten A et al. Catecholamines stimulate interleukin‑6 synthesis in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2001; 281: H14– H21.

12. Kaski JC, Avanzas P, Arroyo‑ Espliguero R. Neopterin – a forgotten biomarker. J Am Coll Cardiol 2003; 42: 1142– 1143.

13. Fay WP. Linking inflammation and thrombosis: Role of C‑ reactive protein. World J Cardiol 2010; 2: 365– 369.

14. Ridker PM. Clinical application of C‑ reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363– 369.

15. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763– 771.

16. Blake GJ, Ridker PM. Inflammatory bio‑ markers and cardiovascular risk prediction. J Intern Med 2002; 252: 283– 294.

17. Blake GJ, Ridker PM. C‑ reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003; 41 (Suppl 4): S37– S42.

18. Bharadwaj D, Stein MP, Volzer M et al. The major receptor for C‑ reactive protein on leukocytes is Fcgamma receptor II. J Exp Med 1999; 190: 585– 590.

19. Lagrand WK, Niessen HW, Wolbink GJ et al. C‑ reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95: 97– 103.

20. Griselli M, Herbert J, Hutchinson WL et al.C‑ reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190: 1733– 1740.

21. Takahashi T, Anzai T, Kaneko H et al. Increased C‑ reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol 2010; 299: H1795– H1804.

22. Ikeda U, Maeda Y, Yamamoto K et al. C‑ Reactive protein augments inducible nitric oxide synthase expression in cytokine‑ stimulated cardiac myocytes. Cardiovasc Res 2002; 56: 86– 92.

23. Koenig W, Sund M, Fröhlich M et al. C‑ reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle‑ aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237– 242.

24. Ridker PM, Cannon CP, Morrow D et al. C‑ reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20– 28.

25. Pietilä K, Harmoinen A, Pöyhönen L et al. Intravenous streptokinase treatment and serum C‑ reactive protein in patients with acute myocardial infarction. Brit Heart J 1987; 58: 225– 229.

26. De Beer FC, Hind CR, Fox KM et al. Measurement of serum C‑ reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982; 47: 239– 243.

27. Pietilä K, Harmoinen A, Hermens W et al. Serum C‑ reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct‑related coronary artery after thrombolytic therapy. Eur Heart J 1993; 14: 915– 919.

28. Beranek JT. C‑ reactive protein and complement in myocardial infarction and postinfarction heart failure. Eur Heart J 1997; 18: 1834– 1836.

29. Ørn S, Manhenke C, Ueland T et al. C‑ reactive protein, infarct size, microvascular obstruction, and left‑ ventricular remodelling following acute myocardial infarction. Eur Heart J 2009; 30: 1180– 1186.

30. Takahashi T, Anzai T, Yoshikawa T et al. Serum C‑ reactive protein elevation in left ventricular remodeling after acute myocardial infarction – role of neurohormones and cytokines. Int J Cardiol 2003; 88: 257– 265.

31. Mather AN, Fairbairn TA, Artis NJ et al. Relationship of cardiac biomarkers and reversible and irreversible myocardial injury following acute myocardial infarction as determined by cardiovascular magnetic resonance. Int J Cardiol 2013; 20: 458– 464.

32. Uehara K, Nomura M, Ozaki Y et al. High‑sensitivity C‑ reactive protein and left ventricular remodeling in patients with acute myocardial infarction. Heart Vessels 2003; 18: 67– 74.

33. Anzai T, Yoshikawa T, Shiraki H et al. C‑ reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q‑ wave acute myocardial infarction. Circulation 1997; 96: 778– 784.

34. Scirica BM, Morrow DA, Cannon CP et al. Clinical application of C‑ reactive protein across the spectrum of acute coronary syndromes. Clin Chem 2007; 53: 1800– 1807.

35. Mega JL, Morrow DA, de Lemos JA et al. B‑type natriuretic peptide at presentation and prognosis in patients with ST‑segment elevation myocardial infarction: an ENTIRE‑ TIMI‑ 23 substudy. J Am Coll Cardiol 2004; 44: 335– 339.

36. Bogaty P, Boyer L, Simard S et al. Clinical utility of C‑ reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease: The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol 2008; 51: 2339– 2346.

37. Kala P, Miklik R. Pharmaco‑ mechanic Antithrombotic Strategies to Reperfusion of the Infarct‑ Related Artery in Patients with ST‑Elevation Acute Myocardial Infarctions. J Cardiovasc Transl Res 2013; 6: 378– 387.

38. Kala P, Kanovsky J, Rokyta R et al. Age‑related treatment strategy and long‑term outcome in acute myocardial infarction patients in the PCI era. BMC Cardiovasc Disord 2012; 12: 31.

39. Mueller C, Buettner HJ, Hodgson JM et al. Inflammation and long‑term mortality after non‑ST elevation acute coronary syndrome treated with a very early invasive strategy in 1,042 consecutive patients. Circulation 2002; 105: 1412– 1415.

40. Schiele F, Meneveau N, Seronde MF et al. C‑ reactive protein improves risk prediction in patients with acute coronary syndromes. Eur Heart J 2010; 31: 290– 297.

41. Pietilä KO, Harmoinen AP, Jokiniitty J et al. Serum C‑ reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow‑up in patients under thrombolytic treatment. Eur Heart J 1996; 17: 1345– 1349.

42. Tommasi S, Carluccio E, Bentivoglio M et al. C‑ reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol 1999; 83: 1595– 1599.

43. Biasucci LM, Liuzzo G, Grillo RL et al. Elevated levels of C‑ reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855– 860.

44. Ridker PM, Cannon CP, Morrow D et al. C‑ reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20– 28.

45. Helánová K, Pařenica J, Dlouhý V et al. The importance of NGAL and cystatin C biomarkers in cardiovascular diseases. Vnitř Lék 2012; 58: 286– 290.

46. Lindahl B, Toss H, Siegbahn A et al. Markers of myocardial damage and inflammation in relation to long‑term mortality in unstable coronary artery disease. N Engl J Med 2000; 343: 1139– 1147.

47. Scirica BM, Sabatine MS, Jarolim P et al. Assessment of multiple cardiac biomarkers in non‑ST‑segment elevation acute coronary syndromes: observations from the MERLIN‑ TIMI 36 trial. Eur Heart J 2011; 32: 697– 705.

48. Apple FS, Pearce LA, Chung A et al. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2007; 53: 874– 881.

49. Januel JM, Harbarth S, Allard R et al. Estimating attributable mortality due to nosocomial infections acquired in intensive care units. Infect Control Hosp Epidemiol 2010; 31: 388– 394.

50. Sykora R. Infectious complications in patients after cardiac arrest undergoing therapeutic hypothermia. Vnitř Lék 2011; 57: 491– 495.

51. Melsen WG, Rovers MM, Koeman M et al. Estimating the attributable mortality of ventilator‑associated pneumonia from randomized prevention studies. Crit Care Med 2011; 39: 2736– 2742.

52. Bergogne‑ Bérézin E. Treatment and prevention of antibiotic associated diarrhea. Int J Antimicrob Agents 2000; 16: 521– 526.

53. Schuetz P, Affolter B, Hunziker S et al. Serum procalcitonin, C‑ reactive protein and white blood cell levels following hypothermia after cardiac arrest: a retrospective cohort study. Eur J Clin Invest 2010; 40: 376– 381.

54. Geppert A, Steiner A, Delle‑ Karth G et al. Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock. Intensive Care Med 2003; 29: 1384– 1389.

55. Toss H, Lindahl B, Siegbahn A et al. Prognostic influence of increased fibrinogen and C‑ reactive protein levels in unstable coronary artery disease. Circulation 1997; 96: 4204– 4210.

56. Morrow DA, Rifai N, Antman EM et al. C‑ reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 1998; 31: 1460– 1465.

57. James SK, Armstrong P, Barnathan E et al. Troponin and C‑ reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: A GUSTO‑ IV substudy. J Am Coll Cardiol 2003; 41: 916– 924.

58. Lindahl B, Toss H, Siegbahn A et al. Markers of myocardial damage and inflammation in relation to long‑term mortality in unstable coronary artery disease. N Engl J Med 2000; 343: 1139– 1147.

59. Oltrona L, Ottani F, Galvani M. Clinical significance of a single measurement of troponin‑I and C‑ reactive protein at admission in 1,773 consecutive patients with acute coronary syndromes. Am Heart J 2004; 148: 405– 415.